• Skip to primary navigation
  • Skip to main content
  • Skip to footer
MotherToBaby

MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

Hide Search
Shopping Cart
Show SearchSearch
866.626.6847
  • About
    • Our Work
    • Our Team
    • Our Partners
  • Exposures
    • Pregnancy and Breastfeeding Exposures
    • Fact Sheets
    • Baby Blogs
    • Podcasts
  • Studies
    • Ongoing Studies
    • What’s Involved?
    • Join Now
    • Health Providers
    • Pharma Industry
    • Publications
  • Health Professionals
    • Patient Education and Provider Resources
    • Refer a Patient
    • Request Materials
    • Meetings
    • FAQs
    • OTIS Membership
  • Media
    • Media Requests
    • Press Releases
    • eNews Sign Up
  • In Your Area
  • OTIS
    • About OTIS
    • OTIS Membership
    • Annual Meeting
    • Member Log-In
    • Donate
  • Contact
  • Show SearchSearch

Statins

July 1, 2021

References:

  • Bateman BT, et al. 2015. Statins and congenital malformations: cohort study. BMJ. 17;350:h1035.
  • Cleary KL, et al. 2014. Challenges of studying drugs in pregnancy for off-label indications: pravastatin for preeclampsia prevention. Semin Perinatol; 38(8):523-7.
  • Constantine MM, Cleary K. 2013. Pravastatin for the prevention of preeclampsia in high-risk pregnant women. Obstet Gynecol; 121(2 0 1).
  • Kazmin A, et al. 2007. Risk of statin use during pregnancy: a systematic review. J Obstet Gynaecol Can; 29(11):906.
  • Kusters DM, et al. 2012. Statin use during pregnancy: a systematic review and meta-analysis. Expert Rev Cardiovasc Ther; 10(3):363-78.
  • Maierean SM, et al. 2018. The potential role of statins in preeclampsia and dyslipidemia during gestation: a narrative review. Expert Opin Investig Drugs; 27(5):427-435.
  • McElhatton P. 2005. Preliminary data on exposure to statins during pregnancy. Reprod Toxicol; 20:471-2.
  • Morton S, Thangaratinam S. 2013. Statins in pregnancy. Curr Opin Obstet Gynecol; 25(6):433-40.
  • Ofori B, et al. 2007. Risk of congenital anomalies in pregnant users of statin drugs. Br J Clin Pharmacol; 64(4):496-509.
  • Taguchi N, et al. 2008. Prenatal exposure to HMG CoA reductase inhibitors: effects on fetal and neonatal outcomes. Reprod Toxicol; 26(2):175-7.
  • Winterfeld U, et al. 2013. Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. BJOG; 120(4):463-71.
  • Wolfgang P, et al. 2004. Pregnancy outcome after medication with HMG-CoA reductase inhibitors in the first trimester. Reprod Toxicol; 19:254-5.

Footer

           

Hot Links

  • Home
  • Exposures
  • Fact Sheets
  • Baby Blogs
  • Podcasts
  • Pregnancy Studies
  • Join a Study Now
  • Healthcare Professionals
  • Refer a Patient
  • Request Materials
  • News
  • Donate
  • Ask An Expert

Current Studies

  • Ankylosing Spondylitis
  • Asthma
  • Coronavirus (COVID-19)
  • Crohn’s Disease
  • Eczema (Moderate-to-Severe)/Atopic Dermatitis
  • Juvenile Idiopathic Arthritis
  • Multiple Sclerosis
  • Pertussis/Tdap vaccine (“Whooping Cough” vaccine)
  • Psoriasis
  • Psoriatic Arthritis
  • Rheumatoid Arthritis
  • Ulcerative Colitis

Contact

Exposure Information Service
866.626.6847

Pregnancy Studies
877.311.8972

Media Inquiries
619.368.3259
nchavez@mothertobaby.org

MotherToBaby, a service of the Organization of Teratology Information Specialists
OTIS Logo

Copyright © 2023 The Organization of Teratology Information Specialists

  • Accessibility
  • Privacy
  • Terms
  • Site Map
^